Pharmacological Measures of Treatment Adherence and Risk of HIV Infection in the VOICE Study.

ABSTRACT:

Background

None of the 3 regimens tested in the VOICE study showed protection against human immunodeficiency virus (HIV) infection in intent-to-treat analyses. Plasma tenofovir concentrations demonstrated poor adherence to the study product among study subjects. Statistical analyses to explore the causal treatment effect on the prevention of HIV infection among adherent individuals are needed.

Methods

We developed an analytical strategy to evaluate whether conventional covariate adjustment removes confounding and thereby reveals a prevention effect among adherent individuals. We applied this strategy to the VOICE study, using 2 dichotomized proxy measures of product use: detection of tenofovir in plasma at least once during follow-up and detection of tenofovir in plasma at t

SUBMITTER: Dai JY 

PROVIDER: S-EPMC4704663 | biostudies-literature | 2016 Feb

REPOSITORIES: biostudies-literature